title: [All-trans retinoic acid-induced erythema nodosum in acute promyelocytic leukemia].
abstract: A 24-year-old woman with acute promyelocytic leukemia was treated with all-trans retinoic acid (ATRA) as a remission induction therapy. After pneumonia in the neutropenic period was successfully treated with antibiotic treatment, there was recurrence of high fever alone, followed by the appearance of erythema nodosum with pain in her upper limbs on day 25 of ATRA therapy. Skin biopsy neither revealed infiltration of leukemic cells nor suggested Sweet's syndrome. We considered the eruptions to be associated with ATRA, and prednisolone (30 mg/day for 5 days) was administered. Although the administration of ATRA was continued until complete remission of the leukemia, the erythema nodosum rapidly disappeared following short-term steroid therapy and no recurrence was observed. ATRA-induced erythema nodosum is rare, however it should be recognized as a possible adverse effect in ATRA therapy.
authors.affiliation: Division of Molecular Analysis of Human Disorders, Department of Bio-signal Analysis, Yamaguchi University Graduate School of Medicine.
authors.forename: Akihiko
authors.initials: A
authors.lastname: Taguchi
authors.forename: Toru
authors.initials: T
authors.lastname: Takahashi
authors.forename: Youhei
authors.initials: Y
authors.lastname: Harima
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Takemoto
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Ando
authors.forename: Jun
authors.initials: J
authors.lastname: Nomiyama
authors.forename: Atsushi
authors.initials: A
authors.lastname: Matsubara
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Yujiri
authors.forename: Yukio
authors.initials: Y
authors.lastname: Tanizawa
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004893:Erythema Nodosum / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage; D012008:Recurrence; D012074:Remission Induction; D016896:Treatment Outcome; D014212:Tretinoin / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D014212:Tretinoin; D011239:Prednisolone